SCHEMBL68072

SCHEMBL68072

COc1cc(N)ncc1-c1[nH]c(-c2ccccc2)nc1-c1ccncc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK13 O15264 12/20 0.57
MAPK12 P53778 12/20 0.57
MAPK11 Q15759 12/20 0.57
MAPK14 Q16539 12/20 0.57
RAF1 P04049 9/20 0.57
MAPK9 P45984 1/20 0.54
ALOX5 P09917 2/20 0.53
GCGR P47871 4/20 0.49
SMPD3 Q9NY59 2/20 0.49
NOX1 Q9Y5S8 1/20 0.49
KDM4E B2RXH2 3/20 0.48
ALDH1A1 P00352 3/20 0.48
MAPT P10636 3/20 0.48
HPGD P15428 3/20 0.48
LMNA P02545 2/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
HTT P42858 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
BRAF P15056 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL67025 0.81 MAPK13 (0.61) MAPK13MAPK12MAPK11MAPK14RAF1
SCHEMBL67449 0.79 MAPK14 (0.61) MAPK13MAPK12MAPK11MAPK14RAF1
SCHEMBL68162 0.78 MAPK13 (0.71) MAPK13MAPK12MAPK11MAPK14RAF1
SCHEMBL15075623 0.77 MAPK13 (0.71) MAPK13MAPK12MAPK11MAPK14RAF1
SCHEMBL27934209 0.77 MAPK13 (0.67) MAPK13MAPK12MAPK11MAPK14RAF1
SCHEMBL67690 0.77 MAPK14 (0.61) MAPK13MAPK12MAPK11MAPK14RAF1
SCHEMBL68452 0.77 MAPK13 (0.70) MAPK13MAPK12MAPK11MAPK14RAF1
SCHEMBL69956 0.75 MAPK13 (0.58) MAPK13MAPK12MAPK11MAPK14RAF1
SCHEMBL67680 0.75 SMPD3 (0.51) MAPK13MAPK12MAPK11MAPK14RAF1
SCHEMBL68343 0.75 MAPK13 (0.58) MAPK13MAPK12MAPK11MAPK14RAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8865732-B2 Heterocyclic compounds and uses thereof NOVARTIS AG (CH) 2014-10-21 US disclosed
US-8865732-B2 Heterocyclic compounds and uses thereof NOVARTIS AG (CH) 2014-10-21 US disclosed
US-20130210818-A1 Novel Heterocyclic Compounds and Uses Thereof NOVARTIS AG (CH) 2013-08-15 US disclosed
US-20130210818-A1 Novel Heterocyclic Compounds and Uses Thereof NOVARTIS AG (CH) 2013-08-15 US disclosed
US-8129394-B2 Heteroaryl-substituted imidazole compounds and uses thereof NOVARTIS AG (CH) 2012-03-06 US disclosed
US-8129394-B2 Heteroaryl-substituted imidazole compounds and uses thereof NOVARTIS AG (CH) 2012-03-06 US disclosed
US-20100003246-A1 Novel heterocyclic compounds and uses therof NOVARTIS AG (CH) 2010-01-07 US disclosed
US-20100003246-A1 Novel heterocyclic compounds and uses therof NOVARTIS AG (CH) 2010-01-07 US disclosed
WO-2009115572-A2 NOVEL HETEROCYCLIC COMPOUNDS AND USES THEROF NOVARTIS AG (CH) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100003246-A1 Novel heterocyclic compounds and uses therof BRAF, ARAF, KRAS MAPK13 178/4885MAPK12 501/4885MAPK11 362/4885
US-20130210818-A1 Novel Heterocyclic Compounds and Uses Thereof BRAF, RAF1, HRAS MAPK13 197/4885MAPK12 353/4885MAPK11 186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.